siltuximab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
siltuximab: clinical details
Prescribing considerations
- Confirm adult multicentric Castleman disease and negative HIV and HHV‑8 status.
- Treat active infections before administration; IL‑6 blockade may suppress fever and CRP responses.
- Review gastrointestinal-perforation risk, hepatic impairment, vaccination plans and medicines with narrow therapeutic indices.
- Record the product name and batch number for biologic traceability.
- Safety and efficacy have not been established in children.
Contraindications and cautions
- Severe hypersensitivity to siltuximab or any excipient.
Monitoring
- Haematology parameters before treatment and at the intervals specified in the SmPC.
- Clinical surveillance for infection even when fever or CRP elevation is absent.
- Infusion-related reactions and hypersensitivity.
- Lipid profile, liver function and clinically relevant renal findings.
- Clinical, biochemical, symptomatic and lymph-node response under specialist care.
Clinical pharmacology
A chimeric human–murine IgG1κ monoclonal antibody that forms stable complexes with soluble bioactive IL‑6, preventing receptor binding. IL‑6 concentrations should not be used as a pharmacodynamic marker during treatment because antibody–IL‑6 complexes interfere with current immunoassays.
Formulation and product differences
- The selected presentation is a single-use vial containing freeze-dried powder that requires aseptic reconstitution and dilution for intravenous infusion.
- Excipients include histidine, histidine hydrochloride monohydrate, polysorbate 80 and sucrose.
- The unopened product requires refrigerated storage, protection from light and must not be frozen.
siltuximab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 100 mg, 400 mg
siltuximab interactions
Formal interaction studies have not been performed. Blocking IL‑6 may restore liver-enzyme activity and alter the handling of some medicines.
Warfarin
Its anticoagulant effect may change when siltuximab is started or stopped, so closer monitoring may be required.
Ciclosporin or theophylline
Blood concentrations may change; concentration monitoring and adjustment by the prescriber may be needed.
Oral contraceptives and other sensitive CYP3A4 substrates
Effectiveness could decrease, so the prescriber should review whether additional precautions are appropriate.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.